CAS 1009119-64-5

Daclatasvir

Descrizione:

Daclatasvir è un farmaco antivirale utilizzato principalmente nel trattamento delle infezioni da virus dell'epatite C (VHC). Funziona come un agente antivirale ad azione diretta, specificamente un inibitore di NS5A, che interferisce con il processo di replicazione virale. Daclatasvir è caratterizzato dalla sua alta potenza contro vari genotipi di VHC ed è spesso utilizzato in combinazione con altri farmaci antivirali per migliorare l'efficacia e ridurre il rischio di resistenza. La sostanza è tipicamente somministrata per via orale e ha un profilo farmacocinetico favorevole, consentendo una somministrazione una volta al giorno. La sua struttura chimica include un complesso arrangiamento di eterocicli, contribuendo al suo meccanismo d'azione e all'efficacia terapeutica. Daclatasvir è generalmente ben tollerato, con un profilo di effetti collaterali che può includere affaticamento, mal di testa e nausea, sebbene effetti avversi gravi siano rari. Come per qualsiasi terapia antivirale, il monitoraggio delle interazioni farmacologiche e l'aderenza ai regimi di trattamento sono cruciali per risultati ottimali nei pazienti sottoposti a trattamento per epatite C.

Formula: C₄₀H₅₀N₈O₆

InChI: InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1

InChI key: InChIKey=FKRSSPOQAMALKA-CUPIEXAXSA-N

SMILES: C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@@H](CCC1)C=2NC(=CN2)C3=CC=C(C=C3)C4=CC=C(C=C4)C=5NC(=NC5)[C@H]6N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC6

Sinonimi:

• Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester
• Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester
• Daclatasvir
• Daclavirocyrl
• Daklanork
• Ebp 883
• Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]c arbamate
• dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
• BMS 790052
• Daclatasvir, >=98%
• Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
• Daklinza
• Daclatasvir-d16
• diMethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)
• DiMethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-iMidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-Methyl-1-oxobutane-2, 1-diyl)dicarbaMate (Related Reference)
• Dacaltasvir
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester Daclatasvir BMS 790052
• BMS-790052(Daclatasvir)
• Dhaka He Wei
• Daclatasvir/EBP883

Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate

CAS: 1009119-64-5

Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate

Formula: C₄₀H₅₀N₈O₆

Purezza: 98%

Peso molecolare: 738.88

Ref: 54-OR1026411

Daclatasvir

CAS: 1009119-64-5

Daclatasvir

Formula: C₄₀H₅₀N₈O₆

Purezza: ≥98%

Peso molecolare: 738.88

Ref: 54-BUP14405

Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester

CAS: 1009119-64-5

Formula: C₄₀H₅₀N₈O₆

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 738.8750

Ref: IN-DA00036K

Daclatasvir-d16

CAS: 1009119-64-5

Formula: C₄₀H₃₄D₁₆N₈O₆

Colore e forma: Yellow Solid

Peso molecolare: 754.99

Ref: 4Z-D-145002

Daclatasvir

CAS: 1009119-64-5

Daclatasvir (EBP 883/BMS-790052) is a potent HCV NS5A inhibitor with EC50 9-50 pM across various genotypes. Phase 3.

Formula: C₄₀H₅₀N₈O₆

Purezza: 99.81% - 99.99%

Colore e forma: Solid

Peso molecolare: 738.88

Ref: TM-T6229

Daclatasvir

Prodotto controllato

CAS: 1009119-64-5

Applications Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
References Gao, M., et al.: Nature, 465(7294), 96 (2010); Bell, T. W., Chem. Med. Chem., 5(10), 1663 (2010);

Formula: C₄₀H₅₀N₈O₆

Colore e forma: Neat

Peso molecolare: 738.88

Ref: TR-D101500

Daclatasvir

CAS: 1009119-64-5

Purezza: 98%

Peso molecolare: 738.385

Ref: 10-F979825

Daclatasvir-d6

Prodotto controllato

CAS: 1009119-64-5

Formula: C₄₀D₆H₄₄N₈O₆

Colore e forma: Neat

Peso molecolare: 744.912

Ref: TR-D101502

Daclatasvir

CAS: 1009119-64-5

Formula: C₄₀H₅₀N₈O₆

Peso molecolare: 738.89

Ref: ST-EA-CP-D71000

Daclatasvir

CAS: 1009119-64-5

Daclatasvir is a direct-acting antiviral agent, which is derived from synthetic chemical sources with a specific mode of action targeting the hepatitis C virus (HCV) replication process. It functions as an inhibitor of the HCV nonstructural protein 5A (NS5A), a vital component necessary for viral RNA replication and virion assembly. By binding to two distinct domains of NS5A, Daclatasvir disrupts its ability to function, thereby effectively halting the replication of the viral genome.

Formula: C₄₀H₅₀N₈O₆

Purezza: Min. 95%

Peso molecolare: 738.88 g/mol

Ref: 3D-FD158832